Published in Urology on January 01, 2003
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol (2008) 1.55
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate (2014) 1.49
Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol (2008) 1.24
A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract (2008) 1.19
Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract (2008) 1.18
Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol (2013) 1.10
Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition. PLoS One (2014) 1.08
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol (2006) 1.04
A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. Rev Urol (2005) 1.02
Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J (2008) 1.02
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging (2008) 1.02
Comparison of clinical trials with finasteride and dutasteride. Rev Urol (2004) 0.97
Lower urinary tract symptoms in men. BMJ (2014) 0.95
Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms. Rev Urol (2009) 0.93
Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. Asian J Androl (2014) 0.90
Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr Ther Res Clin Exp (2004) 0.89
Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol (2009) 0.89
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. Prostate Cancer Prostatic Dis (2010) 0.86
Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence (2011) 0.86
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine (Baltimore) (2015) 0.86
Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it. Ther Adv Urol (2012) 0.86
Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clin Investig (Lond) (2014) 0.82
Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag (2009) 0.81
Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS). BMJ Clin Evid (2011) 0.81
Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin. Patient Relat Outcome Meas (2011) 0.80
Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia. Korean J Urol (2014) 0.80
Medical treatment of benign prostatic hyperplasia. Rev Urol (2011) 0.79
Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol (2004) 0.79
AUA Guidelines and Their Impact on the Management of BPH: An Update. Rev Urol (2004) 0.78
Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag (2007) 0.78
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia. Rev Urol (2005) 0.78
Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol (2016) 0.78
Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea. Int Neurourol J (2010) 0.77
Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clin Interv Aging (2006) 0.77
α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results. Korean J Urol (2012) 0.77
Measurement of benign prostatic hyperplasia treatment effects on male sexual function. Int J Impot Res (2009) 0.75
Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia. Korean J Urol (2011) 0.75
Landmark studies impacting the medical management of benign prostatic hyperplasia. Rev Urol (2003) 0.75
Landmark studies impacting the medical management of benign prostatic hyperplasia. Rev Urol (2003) 0.75
5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec. PLoS One (2017) 0.75
Therapeutic options in the treatment of benign prostatic hyperplasia. Patient Prefer Adherence (2009) 0.75
Best of the 2003 AUA Annual Meeting: Highlights from the 2003 Annual Meeting of the American Urological Association, April 26-May 1, 2003, Chicago, IL. Rev Urol (2003) 0.75
Medical treatment of benign prostatic hyperplasia. Postgrad Med J (2007) 0.75
Doxazosin for the symptomatic treatment of benign prostatic hyperplasia. Curr Urol Rep (2003) 0.75
Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study. Yonsei Med J (2017) 0.75
[Benign prostate hyperplasia]. Urologe A (2006) 0.75
How do I treat and follow my TUNA patients. World J Urol (2006) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol (2007) 9.67
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ (2012) 4.79
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer (2005) 4.55
Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU Int (2012) 4.01
Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies. Int J Epidemiol (2008) 3.56
Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol (2003) 3.31
Breast cancer. Lancet (2005) 3.27
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
'Environment' in cancer causation and etiological fraction: limitations and ambiguities. Carcinogenesis (2007) 3.20
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20
Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol (2004) 3.15
Testosterone therapy in men with untreated prostate cancer. J Urol (2011) 3.08
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer (2005) 3.02
Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet (2003) 2.95
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 2.94
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Tobacco smoking and cancer: a meta-analysis. Int J Cancer (2008) 2.64
Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer (2005) 2.63
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int (2008) 2.60
Adult stem cell therapy of female stress urinary incontinence. Eur Urol (2007) 2.48
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol (2002) 2.37
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Retracted Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet (2007) 2.35
Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci U S A (2009) 2.33
Total reconstruction of the vesico-urethral junction. BJU Int (2008) 2.28
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry (2006) 2.26
The complexities of tracheal intubation with direct laryngoscopy and alternative intubation devices. Ann Emerg Med (2010) 2.24
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Optimizing the outcome of microsurgical subinguinal varicocelectomy using isosulfan blue: a prospective randomized trial. J Urol (2006) 2.15
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood (2006) 2.06
Continuous propofol infusion in 142 critically ill children. Pediatrics (2002) 2.04
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation (2005) 2.01
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
Early diagnosis and straight forward surgery of an asymptomatic primary angiosarcoma of the kidney led to long-term survival. Int J Urol (2006) 1.92
Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study. Am Heart J (2007) 1.86
Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol (2003) 1.84
Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int (2008) 1.83
Anderson-Hynes dismembered pyeloplasty performed using the da Vinci robotic system. Urology (2002) 1.81
Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol (2004) 1.79
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol (2004) 1.71
The challenge of cancer control in Africa. Nat Rev Cancer (2008) 1.71
Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int J Cancer (2006) 1.71
Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology (2007) 1.69
Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate (2005) 1.68
Robotic-assisted laparoscopic partial nephrectomy: surgical technique and clinical outcomes at 1 year. BJU Int (2008) 1.68
Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of moderate-to-severe hot flashes in menopause. Menopause (2014) 1.67
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol (2003) 1.67
Robotic Anderson-Hynes pyeloplasty: 5-year experience of one centre. BJU Int (2007) 1.67
Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol (2005) 1.67
EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila) (2011) 1.65
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol (2004) 1.65
Attention bias toward threat in pediatric anxiety disorders. J Am Acad Child Adolesc Psychiatry (2008) 1.64
Mouthwash and oral cancer risk quantitative meta-analysis of epidemiologic studies. Ann Agric Environ Med (2012) 1.62
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control (2004) 1.59
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int (2008) 1.58
Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. BJU Int (2007) 1.55
The future of the nicotine-addiction market. Lancet (2003) 1.55
Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol (2004) 1.54
Curbing the liver cancer epidemic in Africa. Lancet (2008) 1.54
The prevalence of urinary incontinence in community-dwelling married women: a matter of definition. BJU Int (2004) 1.54
Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction. BJU Int (2008) 1.52
EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol (2012) 1.52
The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int (2007) 1.50
Declining mortality from bladder cancer in Europe. BJU Int (2007) 1.49
Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg (2008) 1.49
The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int (2008) 1.49
Androgen axis in prostate cancer. J Cell Biochem (2006) 1.48
Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet (2006) 1.47
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int (2007) 1.44
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
Giant cystine stone in an infant bladder with no evidence of cystinuria--valence of possible pathomechanisms. Urol Int (2005) 1.44
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol (2011) 1.44
Endoscopic application of dextranomer/hyaluronic acid copolymer in the treatment of vesico-ureteric reflux after renal transplantation. BJU Int (2010) 1.44
Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.43
Functional and histological changes after myoblast injections in the porcine rhabdosphincter. Eur Urol (2007) 1.43
Blunt renal trauma in children: 26 years clinical experience in an alpine region. Eur Urol (2002) 1.42
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol (2004) 1.42
The Physiology of Cardiopulmonary Resuscitation. Anesth Analg (2016) 1.41
Influence of nitrate levels in drinking water on urological malignancies: a community-based cohort study. BJU Int (2005) 1.41
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer (2004) 1.38
Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res (2002) 1.37
Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol (2008) 1.35
Leveling of prostate cancer mortality in Western Europe. Prostate (2004) 1.34
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis (2006) 1.32
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31